



Versartis
Investor Relations Department
4200 Bohannon Drive
Suite 250
Menlo Park, CA 94025
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: VSAR

Last Trade:	19.15
Trade Time:	4:00 PM ET Jul 26, 2017
Change:	0.30 (+1.592%)
Day Range	18.60 - 19.75
52-Week Range	9.05 - 24.00
Volume	163,003

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone to treat growth hormone deficiency (GHD) in children and adults.

Somavaratan is intended to reduce the injection burden of daily therapy and improve therapeutic outcomes through enhanced adherence and convenience with twice-monthly dosing, a fine gauge needle autoinjector device and room temperature storage.

Versartis is currently evaluating somavaratan for the treatment of pediatric ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 1, 2017*
[Versartis Appoints Eric Dobmeier to Board of Directors](#)
- May 22, 2017*
[Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology](#)
- Apr 27, 2017*
[Versartis Reports First Quarter 2017 Financial Results](#)
- Apr 25, 2017*
[Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations](#)
- Apr 3, 2017*
[Versartis Announces Three Year Somavaratan Data at ENDO 2017 Showing Safety and Efficacy in Line with Historical U.S. Daily rhGH Data in Pediatric GHD](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Mar 10, 2017*
[Annual Report \(10-K\)](#)
- Apr 25, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2016*
[Quarterly Report \(10-Q\)](#)